Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nuclear Transmutation03:20

Nuclear Transmutation

18.0K
Nuclear transmutation is the conversion of one nuclide into another. It can occur by the radioactive decay of a nucleus, or the reaction of a nucleus with another particle. The first manmade nucleus was produced in Ernest Rutherford’s laboratory in 1919 by a transmutation reaction, the bombardment of one type of nuclei with other nuclei or with neutrons. Rutherford bombarded nitrogen-14 atoms with high-speed α particles from a natural radioactive isotope of radium and observed...
18.0K
Positron Emission Tomography01:29

Positron Emission Tomography

5.4K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
5.4K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

233
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
233

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Best Practices for Treatment Team Collaboration in the Use of Radiopharmaceutical Therapy in the United States.

JCO oncology practice·2026
Same author

Elective Nodal Radiation Therapy in Localized Prostate Cancer: A Meta-Analysis.

International journal of radiation oncology, biology, physics·2026
Same author

Patient-reported distress and anxiety during cone-beam CT imaging sessions with increased gantry rotation speeds.

Technical innovations & patient support in radiation oncology·2026
Same author

Response to the FDA Dosage Optimization Draft Guidance for Radiopharmaceutical Therapies.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis.

Lancet (London, England)·2026
Same author

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration.

The Lancet. Oncology·2026

Related Experiment Video

Updated: Sep 7, 2025

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

18.0K

Lutetium-177 DOTATATE: A Practical Review.

Angela Y Jia1, Rojano Kashani2, Nicholas G Zaorsky2

  • 1Department of Radiation Oncology, Johns Hopkins University, Baltimore, Maryland.

Practical Radiation Oncology
|June 18, 2022
PubMed
Summary

Peptide receptor radionuclide therapy using [177Lu] Lu-DOTA-[Tyr3]-octreotate significantly improved survival for neuroendocrine tumor (NET) patients. This therapy offers a new radiation-based treatment option for advanced NETs with a good safety profile.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.1K

Related Experiment Videos

Last Updated: Sep 7, 2025

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

18.0K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.1K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Endocrinology

Background:

  • Neuroendocrine tumors (NETs) are diverse, with outcomes influenced by differentiation and grade.
  • Advanced or metastatic NETs often resist standard treatments.
  • Peptide receptor radionuclide therapy (PRRT) shows promise for refractory NETs.

Purpose of the Study:

  • To evaluate the efficacy and safety of [177Lu] Lu-DOTA-[Tyr3]-octreotate in patients with somatostatin receptor-positive gastroenteropancreatic NETs.
  • To compare PRRT with standard therapy in a phase III clinical trial.

Main Methods:

  • The NETTER-1 trial was a phase III study comparing [177Lu] Lu-DOTA-[Tyr3]-octreotate plus octreotide versus octreotide alone.
  • Participants had somatostatin receptor-positive, locally advanced or metastatic gastroenteropancreatic NETs.

Main Results:

  • [177Lu] Lu-DOTA-[Tyr3]-octreotate significantly improved disease-free survival compared to octreotide alone.
  • The treatment demonstrated a favorable toxicity profile.
  • This led to FDA approval for the therapy.

Conclusions:

  • [177Lu] Lu-DOTA-[Tyr3]-octreotate is an effective new treatment for advanced gastroenteropancreatic NETs.
  • It expands the role of radiation therapy in NET management.
  • Ongoing trials will further define its clinical utility.